Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The Phase III clinical SURMOUNT-1 (NCT04184622) for tirzepatide, is expected to be completed in the first half of 2024
These effects are initially mediated by natriuresis and plasma volume contraction, but sustained effects likely reflect additional mechanisms including reduced total body sodium, decrease in intracellular sodium and calcium, and vasodilation
Treatment plans may include medication education, follow-up care, lifestyle guidance, and weight management support
While GHK-Cu is a well-researched topical ingredient, injectable GHK-Cu peptides are neither FDA approved nor regulated and aren't recommended
A consultation with one of our providers helps determine whether GLP-1s are the right fit for each individual
Yoshimura et al., 1996
